Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.410
-0.070 (-2.01%)
At close: Apr 28, 2026, 4:00 PM EDT
3.420
+0.010 (0.30%)
After-hours: Apr 28, 2026, 5:19 PM EDT
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Recursion Pharmaceuticals stock have an average target of 7.50, with a low estimate of 5.00 and a high estimate of 11. The average target predicts an increase of 119.94% from the current stock price of 3.41.
Analyst Consensus: Buy
* Price targets were last updated on Feb 26, 2026.
Analyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 2 | 2 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +75.95% | Feb 26, 2026 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +134.60% | Feb 26, 2026 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $10 → $11 | Hold → Buy | Upgrades | $10 → $11 | +222.58% | Dec 17, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +134.60% | Sep 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +134.60% | Jul 8, 2025 |
Financial Forecast
Revenue This Year
83.73M
from 74.68M
Increased by 12.11%
Revenue Next Year
152.82M
from 83.73M
Increased by 82.52%
EPS This Year
-1.03
from -1.44
EPS Next Year
-0.89
from -1.03
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 110.3M | 336.0M | |
| Avg | 83.7M | 152.8M | |
| Low | 70.1M | 73.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 47.6% | 301.3% | |
| Avg | 12.1% | 82.5% | |
| Low | -6.2% | -12.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.95 | -0.64 | |
| Avg | -1.03 | -0.89 | |
| Low | -1.13 | -0.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.